Education
About Us
Working with TipRanks
Follow Us
PMV Pharmaceuticals (PMVP)
NASDAQ:PMVP
PMVP Stock Chart & Stats
$1.14
-$0.01(-0.65%)
At close: 4:00 PM EST
$1.14
-$0.01(-0.65%)
Day’s Range― - ―
52-Week Range$0.81 - $1.84
Previous CloseN/A
Volume81.53K
Average Volume (3M)229.43K
Market Cap
$60.66M
Enterprise Value-$54.13M
Total Cash (Recent Filing)$129.25M
Total Debt (Recent Filing)$931.00K
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Mar 04, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding53,211,506
10 Day Avg. Volume194,299
30 Day Avg. Volume229,434
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.50
Enterprise Value/Market Cap-0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit845.76
Enterprise Value/Ebitda0.61
Forecast
1Y Price Target
$5.00Price Target Upside338.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash RunwayA multi‑million dollar cash balance is positioned to fund operations into early 2027, reducing near‑term financing pressure while development and regulatory milestones proceed.
Clinical EfficacyRezatapopt produced a high overall response rate with durable tumor responses in the ovarian cancer cohort of the PYNNACLE Phase 2 trial, reinforcing confidence in the drug's clinical activity.
Regulatory PathwayPlanned additional enrollment in the PROC cohort and feedback from a recent FDA meeting support a potential New Drug Application filing if subsequent data remain supportive, which could advance the approval pathway.
Bears Say
Capital And Commercialization RiskA need for additional funding combined with lower‑than‑expected commercial uptake could lead to share dilution and a weaker revenue trajectory than projected.
Clinical Development RiskNegative clinical data or delays in moving candidates into advanced trials could sharply reduce investor confidence and negatively impact the stock.
Regulatory Approval RiskFailure to secure regulatory approval for lead programs would materially limit commercial upside and could trigger a reassessment of valuation.
PMV Pharmaceuticals News
PMVP FAQ
What was PMV Pharmaceuticals’s price range in the past 12 months?
PMV Pharmaceuticals lowest stock price was $0.81 and its highest was $1.84 in the past 12 months.
What is PMV Pharmaceuticals’s market cap?
PMV Pharmaceuticals’s market cap is $60.66M.
When is PMV Pharmaceuticals’s upcoming earnings report date?
PMV Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 46 days.
How were PMV Pharmaceuticals’s earnings last quarter?
PMV Pharmaceuticals released its earnings results on Nov 12, 2025. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.402 by $0.002.
Is PMV Pharmaceuticals overvalued?
According to Wall Street analysts PMV Pharmaceuticals’s price is currently Undervalued.
Does PMV Pharmaceuticals pay dividends?
PMV Pharmaceuticals does not currently pay dividends.
What is PMV Pharmaceuticals’s EPS estimate?
PMV Pharmaceuticals’s EPS estimate is -0.41.
How many shares outstanding does PMV Pharmaceuticals have?
PMV Pharmaceuticals has 53,211,506 shares outstanding.
What happened to PMV Pharmaceuticals’s price movement after its last earnings report?
PMV Pharmaceuticals reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.402. Following the earnings report the stock price went up 6.767%.
Which hedge fund is a major shareholder of PMV Pharmaceuticals?
Currently, no hedge funds are holding shares in PMVP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PMV Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (338.60% Upside)
$5.00 (338.60% Upside)
Blogger Sentiment
Bullish
PMVP Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.55%
12-Months-Change
Fundamentals
Return on Equity
-51.87%
Trailing 12-Months
Asset Growth
-40.11%
Trailing 12-Months
Company Description
PMV Pharmaceuticals
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
PMVP Stock 12 Month Forecast
Average Price Target
$5.00
▲(338.60% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Prelude Therapeutics
―
Gain Therapeutics
―
Immix Biopharma
―
Ownership Overview
12.71% Insiders
8.40% Mutual Funds
52.76% Other Institutional Investors
22.36% Public Companies and
Individual Investors